Phase II study of R-CEOP 1-8 for aggressive non-Hodgkin lymphoma in elderly patients

被引：0
|
作者：
Marelli, M.
Bascialla, L.
Chini, C.
Proserpio, I
Gueli, R.
Pinotti, G.
机构：
[1] Azienda Osped Osped Circolo, UO Oncol Med, Varese, Italy
[2] Fdn Macchi, Varese, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI57 / XI57
页数：1
相关论文
共 50 条
  • [21] Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma
    Borchmann, Peter
    Herbrecht, Raoul
    Wilhelm, Martin
    Morschhauser, Franck
    Hess, Georg
    Cernohous, Paul
    Veals, Susan A.
    Singer, Jack W.
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 620 - 628
  • [22] Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial
    Song, Zheng
    Wang, Huaqing
    Zhang, Huilai
    Zhao, Kuo
    Zhang, Man
    Yang, Fang
    LEUKEMIA & LYMPHOMA, 2017, 58 (04) : 816 - 821
  • [23] AGGRESSIVE NON-HODGKIN LYMPHOMA IN THE ELDERLY - A RETROSPECTIVE STUDY OF 72 PATIENTS WITH CLINICAL-FEATURES AND TREATMENT
    BRICE, P
    LEPAGE, E
    GISSELBRECHT, C
    FIOR, R
    TREDANIEL, J
    DAGAY, MF
    BOIRON, M
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1990, 32 (02): : 153 - 157
  • [24] The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma
    Osmanilhan
    Seval, Guldane Cengiz
    Bozdag, Sinem Civriz
    Toprak, Selami kocak
    Yuksel, Meltem Kurt
    Topcuoglu, Pervin
    Arslan, Onder
    Ozcan, Muhit
    Demirer, Taner
    Gurman, Gunhan
    Beksac, Meral
    BLOOD, 2021, 138
  • [25] ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma
    Santoro, P
    Martinelli, G
    Ferrucci, PF
    Mingrone, W
    Cocorocchio, E
    Conconi, A
    Peccatori, FA
    De Luzio, K
    Mazzetta, C
    Zucca, E
    Cavalli, F
    LEUKEMIA & LYMPHOMA, 2003, 44 (05) : 801 - 806
  • [26] Excellent Outcomes with R-CEOP for Diffuse Large B-Cell Lymphoma in Elderly Patients Not Eligible for Anthracyclines
    Grech, M.
    Gauci, J.
    Theuma, K. -B.
    Gatt, A.
    Camilleri, D. -J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 86 - 87
  • [27] Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 339
  • [28] Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly
    Coiffier, B
    SEMINARS IN ONCOLOGY, 2003, 30 (01) : 21 - 27
  • [29] Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma
    Borghaei, H
    Millenson, M
    Schilder, R
    Alden, M
    Rogatko, A
    Wang, H
    Padavic-Shaller, K
    Smith, MR
    CANCER, 2004, 101 (09) : 2034 - 2041
  • [30] Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies
    Aviles, A
    Nambo, MJ
    Talavera, A
    Garcia, EL
    HuertaGuzman, J
    Maqueo, JCD
    ANTI-CANCER DRUGS, 1997, 8 (10) : 937 - 942
12345